New research exploring the effects of etanercept on cardiovascular disease in treatment-naive, early RA patients suggests a treatment advantage with etanercept, a TNF inhibitor and methotrexate over treatment with methotrexate and a conventional synthetic disease-modifying anti-rheumatic drug…
NEW YORK (Reuters Health)—Disease-modifying antirheumatic drugs (DMARDs) reduce the risk of developing rheumatoid arthritis (RA) in patients with early undifferentiated arthritis, researchers from France report. Several studies have suggested that conventional or biological DMARDs might interfere with the pathogenic process and prevent more established forms of RA, but it remains unclear whether these drugs are…